A company that makes two of the priciest drugs on the market was looking to make profits and didn't care if patients could afford them, a Senate committee said Tuesday, NBC News reported.
Gilead's $1,000-a-pill Sovaldi, which can cure hepatitis, has cost the federal government billions and is too expensive for many patients to afford, the Senate Finance Committee said in a report.
"Gilead pursued a calculated scheme for pricing and marketing its Hepatitis C drug based on one primary goal, maximizing revenue, regardless of the human consequences," Oregon Sen. Ron Wyden, a Democrat, said in a statement.
Sovaldi costs about $84,000 for a weeks-long regimen aimed at eradicating the liver-destroying virus.
U.S. & World
Stories that affect your life across the U.S. and around the world.
Gilead said it cooperated with the investigation and defended its pricing of the drugs. "We respectfully disagree with the conclusions of their report," the company said in a statement.